In 2018, Kuros Biosciences recorded the first sales of its MagnetOs bone graft substitute in the U.S. and Europe and raised capital to fund a phase 2 clinical trial of its spinal fusion product.

Sharonville, Ohio-based Beacon Orthopaedics & Sports Medicine is offering orthobiologic and regenerative medicine treatment options for patients with neck and spine pain, Fox19.com reports.

Royal Biologics is an orthobiologics company focused on regenerative cellular technology.

The FDA plans to crackdown on unsubstantiated and poor quality stem cell therapies in 2019, Law 360 reports.

Axolotl Biologix released the Axolotl Shot, a syringe preloaded with ambient temperature regenerative fluid that physicians can apply to patients during same-day, outpatient visits.

Dakota Dunes, S.D.-based Center for Neurosciences, Orthopaedics & Spine physicians have used platelet rich plasma injections to treat more than 100 joint pain patients, according to KTIV News.

The Japanese Pharmaceuticals and Medical Devices Agency granted DiscGenics approval for a clinical trial notification application for its IDCT, an allogeneic, injectable disc cell therapy for degenerative disc disease.

Kuros Biosciences received FDA 510(k) clearance to extend its MagnetOs Putty indications to use as a standalone bone graft in the extremities and pelvis.

Kuros Biosciences' MagnetOs is a suitable alternative to autograft for spinal fusion when used as a standalone graft, according to an animal study in JOR Spine.

Carmell Therapeutics is a biotechnology company focused on plasma-based bioactive materials.

The global spinal biologics market is predicted to grow at a 3.75 percent compound annual growth rate, reaching $2.36 billion by 2021, according to a Research Cosmos report.

Anika Therapeutics resumed distribution of its solid hyaluronic acid-based treatments after a voluntary, non-safety related recall in the second quarter.

AlloSource received a U.S. patent for its proprietary method to create ProChondrixCR, the company's fresh cryopreserved osteochondral allograft.  

Bio2 Technologies is an orthobiologics company.

The global spine biologics market is projected to grow at a 3.5 percent compound annual growth rate to reach $2.72 billion by the end of 2025, according to a Market Reports World report.

Grand Junction, Colo.-based Vail-Summit Orthopaedics & Neurosurgery is using injectable plasma and stem cells to treat sports-related ligament and tendon injuries, according to an article written by William Sterett, MD, in Summit Daily.

Regenerative medicine company Osiris Therapeutics named Samson Tom as president and CEO.

SpinalCyte received FDA Investigational New Drug clearance for CybroCell, its fibroblast-based therapy to treat degenerative disc disease.

Researchers implanted tissue-engineered spinal discs in a goat model which provided long-term function, according to a study in Science Translational Medicine.

Stability Biologics provides allograft products for spine, orthopedic and wound care applications.